Brief: Aurobindo Pharma Unit Gets Marketing Approval For Trastuzumab Biosimilar Dazublys From European Commission
02/07/2025 12:43
July 2 (Reuters) - Aurobindo Pharma Ltd ARBN.NS: AUROBINDO PHARMA - UNIT GETS MARKETING APPROVAL FOR TRASTUZUMAB BIOSIMILAR DAZUBLYS FROM EUROPEAN COMMISSION Source text: ID:nnAZN430TLT Further company coverage: ARBN.NS ((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Aurobindo Pharma
See all newsBrief: Aurobindo Pharma Gets Tax Order Confirming Total Disputed Amount 46 Million Rupees
India's Aurobindo Pharma falls after US FDA flags observation at Telangana facility
Brief: Aurobindo Pharma Says US FDA Inspected API Manufacturing Facility Of Unit Apitoria Pharma
Brief: Aurobindo Pharma Gets USFDA Final Approval For Beclomethasone Dipropionate HFA Inhalation Aerosol
Brief: Aurobindo Pharma Says US FDA Inspected Unit-IV Of Apitoria Pharma From September 7 To September 11